Celltrion Inc. is reeling from last month’s warning the FDA issued to the Incheon, South Korea-based biopharma company over manufacturing problems at one of its facilities there.
It’s the site where Celltrion makes Inflectra, a biosimilar to Johnson & Johnson’s Remicade product to treat rheumatoid arthritis, Crohn’s disease, psoriasis, and other conditions.
Celltrion and Pfizer Inc., which markets Inflectra in the U.S., said supplies wouldn’t be affected. But beleaguered Teva Pharmaceutical Industries Inc. said the warning might affect how quickly the FDA approves biosimilars to Genentech Inc.’s Rituxan and Herceptin.
Teva and Celltrion, which makes the active pharmaceutical ingredients for Teva’s biosimilars at the same plant, announced last year the FDA had accepted biologics license applications for them.
Apart from the impact on the companies, the FDA warning highlights the need for uniform safety and inspection standards, Alliance for Safe Biologic Medicines Executive Director Michael Reilly told me.
“[T]he Celltrion warning letter is a clarion call for the need for strong global approval standards for biosimilars,” he said.
His organization thinks there shouldn’t be an “easy point of entry” for biosimilars, he said—any biosimilar approved anywhere should come with the same guarantee of safety and efficacy.
“The letter shows that the FDA is paying close attention to the quality and safety of medicines but it does raise issues about the manufacturing processes outside of the U.S. and reinforces the need for a strong pharmacovigilance system,” Reilly said.
Biologic products require special scrutiny, as they’re more complex to make and more sensitive to light changes during manufacturing, among other features, he noted.
Reilly has confidence in the new leadership at the Department of Health and Human Services and the Food and Drug Administration to ensure “rigorous inspections and increased pharmacovigilance” for products coming in to the U.S., “but it is the weaker regulatory authorities that cause me the most concern,” he said.
“The FDA’s resources are not unlimited and their ability to conduct inspections outside the U.S. to discover problems like those at Celltrion is therefore also constrained.”
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)